Newsroom – Erytech

REPORT – ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022

Post author:Marianne Duparc
Post published:June 24, 2022
Post category:Newsroom

ERYTECH Pharma announced that its Annual General Meeting was held on Friday, June 24, 2022.

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022

Post author:Marianne Duparc
Post published:May 24, 2022
Post category:Newsroom

ERYTECH’s shareholders are hereby informed of the Annual General Meeting which will be held on June 24, 2022 at 09:00am CEST at the Hôtel Intercontinental Paris – Le Grand, 2…

ERYTECH to Present at the H.C. Wainwright Global Investment Conference

Post author:Marianne Duparc
Post published:May 17, 2022
Post category:Newsroom

ERYTECH Pharma announced that its CEO, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference. The conference will be held in a hybrid format from May 23-26, 2022,…

ERYTECH Provides Business and Financial Update for the First Quarter of 2022

Post author:Marianne Duparc
Post published:May 12, 2022
Post category:Newsroom

ERYTECH Pharma provided a business and financial update at the end of March 2022.

ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar

Post author:Marianne Duparc
Post published:April 28, 2022
Post category:Newsroom

ERYTECH Pharma announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the…

ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent

Post author:Marianne Duparc
Post published:April 25, 2022
Post category:Newsroom

ERYTECH Pharma announced the sale of its U.S. manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies.

ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology

Post author:Marianne Duparc
Post published:April 6, 2022
Post category:Newsroom

The study confirms the potential of eryaspase (GRASPA®) as an attractive treatment option for acute lymphoblastic leukemia (ALL) patients with hypersensitivity to PEG-asparaginase

ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society

Post author:Marianne Duparc
Post published:April 4, 2022
Post category:Newsroom

ERYTECH Pharma announced the presentation of its novel red blood cell vesiculation technology at the 24th Meeting of the European Red Cell Society (ERCS), taking place from April 7 to…

ERYTECH to Participate in the Upcoming April Investor Conferences

Post author:Marianne Duparc
Post published:March 28, 2022
Post category:Newsroom

ERYTECH Pharma today announced their participation in upcoming investor conferences and invites investors to participate in one-on-one meetings.

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021

Post author:Marianne Duparc
Post published:March 11, 2022
Post category:Newsroom

ERYTECH Pharma (Nasdaq & Euronext: ERYP) provided a business update and an update on its cash position at the end of December 2021.